Engineered biomaterials for development of nucleic acid vaccines |
Yang, Jun
(National Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences)
Li, Yan (National Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences) Jin, Shubin (CAS Key Laboratory for Biological Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology) Xu, Jing (CAS Key Laboratory for Biological Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology) Wang, Paul C (Laboratory of Molecular Imaging, Department of Radiology, Howard University) Liang, Xing-Jie (CAS Key Laboratory for Biological Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology) Zhang, Xin (National Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences) |
1 | Chakravarthy KV, Bonoiu AC, Davis WG, Ranjan P, Ding H, Hu R, et al. Gold nanorod delivery of an ssRNA immune activator inhibits pandemic H1N1 influenza viral replication. Proc Natl Acad Sci U S A. 2010;107(22):10172-7. DOI |
2 | Salem AK, Searson PC, Leong KW. Multifunctional nanorods for gene delivery. Nat Mater. 2003;2(10):668-71. DOI |
3 | Almeida JPM, Figueroa ER, Drezek RA. Gold nanoparticle mediated cancer immunotherapy. Nanomedicine. 2014;10(3):503-14. DOI |
4 | Xu L, Liu Y, Chen Z, Li W, Liu Y, Wang L, et al. Surface-Engineered Gold Nanorods: Promising DNA Vaccine Adjuvant for HIV-1 Treatment. Nano Lett. 2012;12:2003-12. DOI |
5 | Grant EV, Thomas M, Fortune J, Klibanov AM, Letvin NL. Enhancement of plasmid DNA immunogenicity with linear polyethylenimine. Eur J Immunol. 2012;42:2937-48. DOI |
6 | Patnaik S, Gupta KC. Novel polyethylenimine-derived nanoparticles for in vivo gene delivery. Expert Opin Drug Deliv. 2013;10(2):215-28. DOI |
7 | Huang R, Liu S, Shao K, Han L, Ke W, Liu Y, et al. Evaluation and mechanism studies of PEGylated dendrigraft poly-L-lysines as novel gene delivery vectors. Nanotechnology. 2010;21(26):265101-11. DOI |
8 | Hofman J, Buncek M, Haluza R, Ludvik S, Ledvina M, Cigler P. In vitro transfection mediated by dendrigraft poly(L-lysines): the effect of structure and molecule size. Macromol Biosci. 2013;13(2):167-76. DOI |
9 | Little SR, Lynn DM, Puram SV, Langer R. Formulation and characterization of poly (beta amino ester) microparticles for genetic vaccine delivery. J Control Release. 2005;107(3):449-62. DOI |
10 | Little SR, Lynn DM, Ge Q, Anderson DG, Puram SV, Chen J, et al. Poly-beta amino ester-containing microparticles enhance the activity of nonviral genetic vaccines. Proc Natl Acad Sci U S A. 2004;101(26):9534-9. DOI |
11 |
Shen Y, Tang H, Zhan Y, Kirk EAV, Murdoch WJ. Degradable Poly( |
12 | Zhang B, Ma X, Murdoch W, Radosz M, Shen Y. Bioreducible poly(amido amine)s with different branching degrees as gene delivery vectors. Biotechnol Bioeng. 2013;110:990-8. DOI |
13 | Huang B, Kukowska-Latallo JF, Tang S, Zong H, Johnson KB, Desai A, et al. The facile synthesis of multifunctional PAMAM dendrimer conjugates through copper-free click chemistry. Bioorg Med Chem Lett. 2012;22(9):3152-6. DOI |
14 | Zhang X, Sharma KK, Boeglin M, Ogier J, Mainard D, Voegel J-C, et al. Transfection ability and intracellular DNA pathway of nanostructured gene-delivery systems. Nano Lett. 2008;8(8):2432-6. DOI |
15 | Ma Y-F, Yang Y-W. Delivery of DNA-based cancer vaccine with polyethylenimine. Eur J Pharm Sci. 2010;40(2):75-83. DOI |
16 | Akinc A, Thomas M, Klibanov AM, Langer R. Exploring polyethyleniminemediated DNA transfection and the proton sponge hypothesis. J Gene Med. 2005;7(5):657-63. DOI |
17 | Negash T, Liman M, Rautenschlein S. Mucosal application of cationic poly(d, l-lactide-co-glycolide) microparticles as carriers of DNA vaccine and adjuvants to protect chickens against infectious bursal disease. Vaccine. 2013;31:3656-62. DOI |
18 | Zhou X, Liu B, Yu X, Zha X, Zhang X, Chen Y, et al. Controlled release of PEI/DNA complexes from mannose-bearing chitosan microspheres as a potent delivery system to enhance immune response to HBV DNA vaccine. J Control Release. 2007;121(3):200-7. DOI |
19 | Li M, Jiang Y, Xu C, Zhang Z, Sun X. Enhanced immune response against HIV-1 induced by a heterologous DNA prime-adenovirus boost vaccination using mannosylated polyethyleneimine as DNA vaccine adjuvant. Int J Nanomedicine. 2013;8:1843-54. |
20 | Sun X, Chen S, Han J, Zhang Z. Mannosylated biodegradable polyethyleneimine for targeted DNA delivery to dendritic cells. Int J Nanomedicine. 2012;7:2929-42. |
21 | Mannisto M, Vanderkerken S, Toncheva V, Elomaa M, Ruponen M, Schacht E, et al. Structure-activity relationships of poly(L-lysines): effects of pegylation and molecular shape on physicochemical and biological properties in gene delivery. J Control Release. 2002;83(1):169-82. DOI |
22 | Green JJ, Zugates GT, Tedford NC, Huang Y-H, Griffith LG, Lauffenburger DA, et al. Combinatorial modification of degradable polymers enables transfection of human cells comparable to adenovirus. Adv Mater. 2007;19:2836-42. DOI |
23 | Liu Z, Lv D, Liu S, Gong J, Wang D, Xiong M, et al. Alginic acid-coated chitosan nanoparticles loaded with legumain DNA vaccine: effect against breast cancer in mice. PLoS One. 2013;8(4):e60190. DOI |
24 | Yao W, Peng Y, Du M, Luo J, Zong L. Preventative vaccine-loaded mannosylated chitosan nanoparticles intended for nasal mucosal delivery enhance immune responses and potent tumor immunity. Mol Pharmaceutics. 2013;10:2904-14. DOI |
25 | Feng G, Jiang Q, Xia M, Lu Y, Qiu W, Zhao D, et al. Enhanced immune response and protective effects of nano-chitosan-based DNA vaccine encoding T cell epitopes of Esat-6 and FL against mycobacterium tuberculosis infection. PLoS One. 2013;8(4):e61135. DOI |
26 | Rudra JS, Tian YF, Jung JP, Collier JH. A self-assembling peptide acting as an immune adjuvant. Proc Natl Acad Sci U S A. 2010;107(2):622-7. DOI |
27 | Rudra JS, Sun T, Bird KC, Daniels MD, Gasiorowski JZ, Chong AS, et al. Modulating Adaptive Immune Responses to Peptide Self-Assemblies. ACS Nano. 2012;6(2):1557-64. DOI |
28 | Cui J, Rose RD, Best JP, Johnston APR, Alcantara S, Liang K, et al. Mechanically tunable, self-adjuvanting nanoengineered polypeptide particles. Adv Mater. 2013;25(25):3468-72. DOI |
29 | Tian Y, Wang H, Liu Y, Mao L, Chen W, Zhu Z, et al. A peptide-based nanofibrous hydrogel as a promising DNA nanovector for optimizing the efficacy of HIV vaccine. Nano Lett. 2014;14:1439-45. DOI |
30 | Minigo G, Scholzen A, Tang CK, Hanley JC, Kalkanidis M, Pietersz GA, et al. Poly-l-lysine-coated nanoparticles: a potent delivery system to enhance DNA vaccine efficacy. Vaccine. 2007;25:1316-27. DOI |
31 | Henriksen-Lacey M, Korsholm KS, Andersen P, Perrie Y, Christensen D. Liposomal vaccine delivery systems. Expert Opin Drug Deliv. 2011;8(4):505-19. DOI |
32 | Un K, Kawakami S, Suzuki R, Maruyama K, Yamashita F, Hashida M. Development of an ultrasound-responsive and mannose-modified gene carrier for DNA vaccine therapy. Biomaterials. 2010;31:7813-26. DOI |
33 | Perrie Y, Frederik PM, Gregoriadis G. Liposome-mediated DNA vaccination: the effect of vesicle composition. Vaccine. 2001;19:3301-10. DOI |
34 | Watson DS, Endsley AN, Huang L. Design considerations for liposomal vaccines: influence of formulation parameters on antibody and cellmediated immune responses to liposome associated antigens. Vaccine. 2012;30(13):2256-72. DOI |
35 | Ginn SL, Alexander IE, Edelstein ML, Abedi MR, Wixon J. Gene therapy clinical trials worldwide to 2012 - an update. J Gene Med. 2013;15:65-77. DOI |
36 | Stopeck AT, Jones A, Hersh EM, Thompson JA, Finucane DM, Gutheil JC, et al. Phase II study of direct intralesional gene transfer of allovectin-7, an HLA-B7/beta2-microglobulin DNA-liposome complex, in patients with metastatic melanoma. Clin Cancer Res. 2001;7(8):2285-91. |
37 | DeMuth PC, Min Y, Huang B, Kramer JA, Miller AD, Barouch DH, et al. Polymer multilayer tattooing for enhanced DNA vaccination. Nat Mater. 2013;12(4):367-76. DOI |
38 | Pollard C, Rejman J, Haes WD, Verrier B, Gulck EV, Naessens T, et al. Type I IFN counteracts the induction of antigen-specific immune responses by lipid-based delivery of mRNA vaccines. Mol Ther. 2013;21(1):251-9. DOI |
39 | Geall AJ, Verma A, Otten GR, Shaw CA, Hekele A, Banerjee K, et al. Nonviral delivery of self-amplifying RNA vaccines. Proc Natl Acad Sci U S A. 2012;109(36):14604-9. DOI |
40 | Jenner E. An inquiry into the causes and effects of the variolae vaccinae, a disease discovered in some of the western counties of England, particularly Gloucestershire, and known by the name of the cow pox. 1798, New York: General Books. |
41 | Behbehani AM. The smallpox story: life and death of an old disease. Microbiol Rev. 1983;47(4):455-509. |
42 | Peek LJ, Middaugh CR, Berkland C. Nanotechnology in vaccine delivery. Adv Drug Deliv Rev. 2008;60(8):915-28. DOI |
43 | Kubba AK, Taylor P, Graneek B, Strobel S. Non-responders to hepatitis B vaccination: a review. Commun Dis Public Health. 2003;6:106-12. |
44 | Plotkin SA. Vaccines: past, present and future. Nat Med. 2005;11(4 Suppl):S5-11. |
45 | Plotkin SA, Orenstein WA, Offit PA. Vaccines. Philadelphia: Saunders; 2008. |
46 | Laddy DJ, Weiner DB. From plasmids to protection: a review of DNA vaccines against infectious diseases. Int Rev Immunol. 2006;25(3-4):99-123. DOI |
47 | Chiarella P, Massi E, Robertis MD, Fazio VM, Signori E. Strategies for effective naked-DNA vaccination against infectious diseases. Recent Pat Antiinfect Drug Discov. 2008;3(2):93-101. DOI |
48 | Rice J, Ottensmeier CH, Stevenson FK. DNA vaccines: precision tools for activating effective immunity against cancer. Nat Rev Cancer. 2008;8(2):108-20. DOI |
49 | Stevenson FK, Ottensmeier CH, Johnson P, Zhu D, Buchan SL, McCann KJ, et al. DNA vaccines to attack cancer. Proc Natl Acad Sci U S A. 2004;101 Suppl 2:14646-52. DOI |
50 | Ferrera F, Lacava A, Rizzi M, Hahn BH, Indiveri F, Filaci G. Gene vaccination for the induction of immune tolerance. Ann N Y Acad Sci. 2007;1110:99-111. DOI |
51 | Richard W, Sandra S, Elisabeth R, Fatima F, Josef T. Prophylactic mRNA vaccination against allergy. Curr Opin Allergy Clin Immunol. 2010;10(6):567-74. DOI |
52 | Sardesai NY, Weiner DB. Electroporation delivery of DNA vaccines: prospects for success. Curr Opin Immunol. 2011;23(3):421-9. DOI |
53 | Porgador A, Irvine KR, Iwasaki A, Barber BH, Restifo NP, Germain RN. Predominant role for directly transfected dendritic cells in antigen presentation to CD8+ T cells after gene gun immunization. J Exp Med. 1998;188(6):1075-82. DOI |
54 | Kutzler MA, Weiner DB. DNA vaccines: ready for prime time? Nat Rev Genet. 2008;9(10):776-88. DOI |
55 | Ledgerwood JE, Pierson TC, Hubka SA, Desai N, Rucker S, Gordon IJ, et al. A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial. J Infect Dis. 2011;203(10):1396-404. DOI |
56 | Martin JE, Pierson TC, Hubka S, Rucker S, Gordon IJ, Enama ME, et al. A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial. J Infect Dis. 2007;196(12):1732-40. DOI |
57 | Liu MA, Ulmer JB. Human clinical trials of plasmid DNA vaccines. Adv Genet. 2005;55:25-40. DOI |
58 | Buchan S, Gronevik E, Mathiesen I, King CA, Stevenson FK, Rice J. Electroporation as a "prime/boost" strategy for naked DNA vaccination against a tumor antigen. J Immunol. 2005;174(10):6292-8. DOI |
59 | Johansson DX, Ljungberg K, Kakoulidou M, Liljestrom P. Intradermal electroporation of naked replicon RNA elicits strong immune responses. PLoS One. 2012;7(1):e29732. DOI |
60 | Yang J, Liu H, Zhang X. Design, preparation and application of nucleic acid delivery carriers. Biotechnol Adv. 2014;32(4):804-917. DOI |
61 | Mora-Solano C, Collier JH. Engaging adaptive immunity with biomaterials. J Mater Chem B Mater Biol Med. 2014;2(17):2409-21. DOI |
62 | Rodriguez-Gascon A, Pozo-Rodriguez A, Solinis MA. Development of nucleic acid vaccines: use of self-amplifying RNA in lipid nanoparticles. Int J Nanomedicine. 2014;9:1833-43. |
63 | Marrack P, McKee AS, Munks MW. Towards an understanding of the adjuvant action of aluminium. Nat Rev Immunol. 2009;9(4):287-93. DOI |
64 | Ulmer JB, DeWitt CM, Chastain M, Friedman A, Donnelly JJ, McClements WL, et al. Enhancement of DNA vaccine potency using conventional aluminum adjuvants. Vaccine. 2000;18:18-28. |
65 | Wang S, Liu X, Fisher K, Smith JG, Chen F, Tobery TW, et al. Enhanced type I immune response to a hepatitis B DNA vaccine by formulation with calcium- or aluminum phosphate. Vaccine. 2000;18:1227-35. DOI |
66 | Correia-Pintoa JF, Csaba N, Alonso MJ. Vaccine delivery carriers: insights and future perspectives. Int J Pharm. 2013;440(1):27-38. DOI |
67 | Tomljenovic L, Shaw CA. Aluminum vaccine adjuvants: are they safe? Curr Med Chem. 2011;18(17):2630-7. DOI |
![]() |